Haleon shares edged higher in London on Tuesday after Goldman Sachs added the consumer-health group to its European Conviction List, a roster of the bank’s most differentiated buy ideas. The maker of Sensodyne toothpaste and Panadol and Advil painkillers was up 0.1% at 372.6 pence by 0959 GMT, within a 370.4p–373.8p session range; the stock has traded between 274.4p and 419.5p over the past year. In a note dated Monday, Goldman set a 12-month price target of 440 pence and said Haleon should benefit as U.S. inventory dynamics normalize and emerging-market penetration rises; it also added Bayer and removed AstraZeneca, among others. Investing.com